Palvella Therapeutics, Inc. · NASDAQ:PVLA

Palvella Therapeutics — Technical Presentation (September 2020)

22 slides from Palvella Therapeutics's technical presentation, Sep 20, 2020

  1. Slide 1: A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule

    A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies Authors: Sarina Piha-Paul1, Johanna Bendell2, Anthony Tolcher3, Sara Hurvitz4, Anuradha Krishnamurthy5, Anthony El-Khoueiry6, Amita Patnaik7, Rachna Shroff8, Anne Noonan9, Paula

  2. Slide 2: Disclosure Information

    Disclosure Information Arog Pharmaceuticals – Research Support AstraZeneca – Research Support, Consulting Bristol-Myer Squibb – Research Support, Consulting GEOFFREY KU Daiichi Sankyo – Research Support Reports relationships Eli Lilly – Consulting with the following: Merck – Research Support, Consul

  3. Slide 3: PRS-343, a HER2 4-1BB Bispecific, Drives 4-1BB Agonism in the Tumor Microenvironment

    PRS-343, a HER2 4-1BB Bispecific, Drives 4-1BB Agonism in the Tumor Microenvironment in HER2 Positive Solid Tumors CLINICALLY-RELEVANT HER2-targeting moiety of the drug 4-1BB cross-linking ameliorates BIOMARKERS localizes to the tumor microenvironment T-cell exhaustion and is critical and facilitate

  4. Slide 4: Study Design: Monotherapy and Combination with Atezolizumab

    Study Design: Monotherapy and Combination with Atezolizumab Dose Levels Primary Objectives Secondary Objectives • Characterize safety profile • Assess potential Monotherapy Dose Levels in Dose of PRS-343 and in immunogenicity Combination with Dose Levels (mg/kg) 1200mg Atezolizumab combination with

  5. Slide 5: Key Enrollment Criteria: Monotherapy and Combination with Atezolizumab

    Key Enrollment Criteria: Monotherapy and Combination with Atezolizumab Inclusion Criteria Exclusion Criteria • Diagnosis of HER2+ advanced/metastatic solid tumor • Ejection fraction below the lower limit of malignancy that has progressed on standard therapy normal with trastuzumab and/or pertuzumab

  6. Slide 6: Baseline Characteristics Monotherapy and Combination with Atezolizumab

    Baseline Characteristics Monotherapy and Combination with Atezolizumab All Subjects (n = 74, 41) In Combination with In Combination with Characteristic Monotherapy; n (%) Primary Cancer Type Monotherapy; n (%) Atezolizumab; n (%) Atezolizumab; n (%) Age, Median (range) 63 (24–92) 59 (26-87) Gastroes

  7. Slide 7: Monotherapy

    Monotherapy A Phase 1, Open-label, Dose Escalation Study of PRS-343 in Patients with HER2-Positive Advanced or Metastatic Solid Tumors 7

  8. Slide 8: Treatment-Related Adverse Events for Monotherapy

    Treatment-Related Adverse Events for Monotherapy All Subjects Monotherapy Occurred in > 1 Patient n = 145 (%) % Grade 3 Infusion Related Reaction 27 (19%) 3 (2%) Fatigue 11 (8%) 1 (1%) Nausea 11 (8%) Vomiting 8 (6%) Chills 8 (6%) Abdominal pain Anemia 2 (1%) 1 (1%) Anorexia Arthalgia 2 (1%) Asthenia

  9. Slide 9: Summary of Responses at Active Dose Range of PRS-343 in Monotherapy

    Summary of Responses at Active Dose Range of PRS-343 in Monotherapy Based on clinical data, serum concentration of > 20 µg/ml defines active dose range (beginning at Cohort 9) Cohort 13b 12b 11c Obi 11b 11 10 9 Total 18 mg/kg, 12 mg/kg, 8 mg/kg, 8 mg/Kg, 8 mg/kg, 8 mg/kg, 5 mg/kg, 2.5 mg/kg, Best Re

  10. Slide 10: Increase in CD8+ T Cells and Circulating Soluble 4-1BB Support 4-1BB Engagement

    Increase in CD8+ T Cells and Circulating Soluble 4-1BB Support 4-1BB Engagement by PRS-343 Biopsy Biopsy Pre-dose PRS-343 PRS-343 Post-dose (Cycle 1 Day 1) (Cycle 2 Day 1) (Cycle 2 Days 2-8) * 30000 10/25 patients evaluated 21/43 patients evaluated 6 Fold induction CD8+ Tcells * Unpaired 2 tailed t-

  11. Slide 11: Gastric Cancer Patient (107-012) with PR

    Gastric Cancer Patient (107-012) with PR Patient Profile, Treatment History and Treatment Outcome Patient Profile Oncology Treatment History Duration • Cohort 11b | 8 mg/kg every two weeks Trastuzumab, Pembrolizumab • 80-year old woman; initial diagnosis in June 2017 July 2017 – June 2018 + Capecita

  12. Slide 12: CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase in Gastric Patient

    CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase Post-Treatment in responding Gastric Cancer Patient (107-012) C4 Post-treatment Baseline CD8 fold change: 5.7 CD8Ki67 fold change: 5.8 1.9 x 2000 CD8 pre [n/mm2]: 38 CD8 pre [n/mm2]: 16 3 increase Fold Change to Predose CD8 +Ki67+ T ce

  13. Slide 13: Rectal Cancer Patient (103-021) with CR

    Rectal Cancer Patient (103-021) with CR Patient Profile, Treatment History and RECIST Oncology Treatment History Duration Monotherapy: Rectal Cancer Patient with Confirmed CR Capecitabine + XRT Apr-May 2017 • Cohort 13b | 18 mg/kg Q2W • FoundationOne Her2 Neoadjuvant Folfox May-Sep 2017 • 59-year-ol

  14. Slide 14: CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase in Rectal Patient

    CD8+ T Cell Numbers in the Tumor and Circulating s4-1BB Increase Post-Treatment in CR Rectal Cancer Patient (103-021) C6 Post-treatment C2 Post-treatment Baseline CD8 fold change: 2.3 CD8 pre [n/mm2]: 238 6 6000 8 .2 x F o ld C h a n g e to B a s e lin e in c re a s e 700 CD8 + T cells (n/mm2) s 4 1

  15. Slide 15: Combination Therapy with Atezolizumab

    Combination Therapy with Atezolizumab A Phase 1B, Open-label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients with Specific HER2-Positive Advanced or Metastatic Solid Tumors 15

  16. Slide 16: PRS-343 + Atezolizumab Duration of Exposure

    PRS-343 + Atezolizumab Duration of Exposure C2D21 C6D21 C10D21 C14D21 C18D21 C22D21 C24D21 Ovarian 102-122 Cohort 7 (8mg/kg) Bladder 111-111 BCA 102-120 Cohort 6 (5mg/kg) NSCLC 113-104 Cohort 5 (2.5mg/kg) Ovarian 112-106 Lung 107-104 Cohort 4 (1mg/kg) Gallbladder 107-103 CUP 102-115 Rectal 113-102 P

  17. Slide 17: Treatment-Related Adverse Events for Combination with Atezolizumab

    Treatment-Related Adverse Events for Combination with Atezolizumab All Subjects Combination with Atezolizumab Occurred in > 1 Patient n = 148 (%) % Grade 3 Infusion Related Reaction 38 (26%) 3 (2%) Fatigue 12 (8%) Nausea 8 (5%) Vomiting 38 (26%) Chills Abdominal pain 2 (1%) Anemia 4 (3%) 2 (1%) Anor

  18. Slide 18: Soluble 4-1BB Increases in Active Dose Cohorts & Clinical Benefit

    Soluble 4-1BB Increases in Active Dose Cohorts & Clinical Benefit is Associated with Tumoral Immune Cell Activation 4-1BB target engagement Soluble 4-1BB in serum CD8+ T cell Numbers CD8+ T cell Proliferation Tumor-localized activity IHC on tumor tissue Patients with prolonged clinical benefit show

  19. Slide 19: Breast Cancer Patient (108-101) with PR

    Breast Cancer Patient (108-101) with PR Patient Profile, Treatment History and RECIST Oncology Treatment History Duration PRS-343+Atezolizumab: Breast Cancer Patient with PR Trastuzumab/Docetaxel/ • Cohort 6 | 5 mg/kg Q3W + • FISH HER2/CEP17 ratio 2.4, Sep 2011-Jul 2013 Tamoxifen/Carboplatin 1200mg

  20. Slide 20: Tumoral and Circulating s4-1BB Increase Post-Treatment in PR Breast Cancer Patient

    Tumoral and Circulating s4-1BB Increase Post- Treatment in PR Breast Cancer Patient (108-101) CD8+ T cell Numbers CD8+ T cell Proliferation Soluble 4-1BB 2 CD8+ T 1200 4000 Abs. CD8+ T cells / 2 CD8+Ki67+ T cells per mm2 150 / tumor mm s4-1BB [pg/ml] +Ki67+ of 1000 3000 CD8numbers mm2 Absolute numbe

  21. Slide 21: Conclusions

    Conclusions Acceptable safety profile in all doses and schedules tested in monotherapy as well as in combination with atezolizumab Demonstrated durable anti-tumor activity in heavily pre-treated patient population across multiple tumor types, including those usually not responsive to immune therapy;

  22. Slide 22: Acknowledgements

    Acknowledgements Patients, their families and caregivers Investigators, as well as their site personnel Monotherapy Combination with Atezolizumab Study 0416 (NCT03330561 A Phase 1, Open-label, Dose Study 0818 (NCT03650348, A Phase 1B, Open-label, Escalation Study of PRS-343 in Patients with HER2-Pos

Palvella Therapeutics — Technical Presentation (September 2020) on 6ix